High-dose Erythropoietin for Asphyxia and Encephalopathy
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen
to the brain near the time of birth. This results in death or neurologic disabilities
including cerebral palsy and cognitive impairment in up to half of affected infants. This
clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual
therapy) will improve outcomes for infants suffering from HIE.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Boston University Children's Hospital Los Angeles Children's Hospital Medical Center, Cincinnati Children's Hospital of Philadelphia Children's National Research Institute Children's Research Institute Cook Children's Medical Center Indiana University Johns Hopkins University Mednax Center for Research, Education and Quality Mednax Center for Research, Education, Quality and Safety Nationwide Children's Hospital Northwestern Stanford University University of California, Davis University of Chicago University of Minnesota University of Minnesota - Clinical and Translational Science Institute University of New Mexico University of North Carolina University of Pittsburgh University of Texas University of Utah University of Washington Vanderbilt University Washington University School of Medicine